Manou Overstijns, István Csók, Marco Bissolo, Christian Scheiwe, Peter Reinacher, Jürgen Beck, Roland Roelz
{"title":"主动血液清除和延迟脑缺血预防治疗可减少动脉瘤性蛛网膜下腔出血患者分流依赖性脑积水。","authors":"Manou Overstijns, István Csók, Marco Bissolo, Christian Scheiwe, Peter Reinacher, Jürgen Beck, Roland Roelz","doi":"10.1227/neu.0000000000003756","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Chronic shunt-dependent hydrocephalus (CSH) is a common and serious complication after aneurysmal subarachnoid hemorrhage (aSAH). Active blood clearance and delayed cerebral ischemia prevention (ABCD) therapy, using intrathecal urokinase and nimodipine irrigation, aims to enhance blood clearance and prevent vasospasm. This study evaluates whether ABCD therapy reduces the incidence of CSH in aSAH patients.</p><p><strong>Methods: </strong>A matched-pairs analysis was performed and 160 aSAH patients who had received ABCD therapy were compared with 160 controls. Patients were paired on the basis of a best fit model including the World Federation of Neurological Surgeons grade, age, cerebral herniation, intracerebral hemorrhage, and the initial Hijdra score. Patients were stratified by Hijdra score to account for blood load. The incidence of CSH was compared between groups using χ2 tests, whereas a multivariable cause-specific Cox proportional hazards model was used to assess time to shunt-dependent hydrocephalus. In addition, multivariate logistic regression was performed to identify predictors of hydrocephalus.</p><p><strong>Results: </strong>The incidence of CSH was significantly lower in the ABCD group (19.4%) compared with the standard care group (31.3%, P = .015). Subgroup analysis revealed that patients with the highest blood load (Hijdra 30-42) experienced a significant reduction in hydrocephalus (45.8% vs 22.5%, P = .026). By contrast, no significant effects were observed in patients with lower Hijdra scores. Multivariate analysis confirmed that the Hijdra score was a significant predictor of CSH in the standard care group (P = .008) but not in the ABCD-treated group (P = .843).</p><p><strong>Conclusion: </strong>aSAH patients selected for ABCD therapy had a significantly lower incidence of shunt-dependent hydrocephalus compared with matching controls. ABCD therapy may be an important preventive strategy in patients with severe subarachnoid hemorrhage.</p>","PeriodicalId":19276,"journal":{"name":"Neurosurgery","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Active Blood Clearance and Delayed Cerebral Ischemia Prevention Therapy Reduces Shunt-Dependent Hydrocephalus in Patients With Aneurysmal Subarachnoid Hemorrhage.\",\"authors\":\"Manou Overstijns, István Csók, Marco Bissolo, Christian Scheiwe, Peter Reinacher, Jürgen Beck, Roland Roelz\",\"doi\":\"10.1227/neu.0000000000003756\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Chronic shunt-dependent hydrocephalus (CSH) is a common and serious complication after aneurysmal subarachnoid hemorrhage (aSAH). Active blood clearance and delayed cerebral ischemia prevention (ABCD) therapy, using intrathecal urokinase and nimodipine irrigation, aims to enhance blood clearance and prevent vasospasm. This study evaluates whether ABCD therapy reduces the incidence of CSH in aSAH patients.</p><p><strong>Methods: </strong>A matched-pairs analysis was performed and 160 aSAH patients who had received ABCD therapy were compared with 160 controls. Patients were paired on the basis of a best fit model including the World Federation of Neurological Surgeons grade, age, cerebral herniation, intracerebral hemorrhage, and the initial Hijdra score. Patients were stratified by Hijdra score to account for blood load. The incidence of CSH was compared between groups using χ2 tests, whereas a multivariable cause-specific Cox proportional hazards model was used to assess time to shunt-dependent hydrocephalus. In addition, multivariate logistic regression was performed to identify predictors of hydrocephalus.</p><p><strong>Results: </strong>The incidence of CSH was significantly lower in the ABCD group (19.4%) compared with the standard care group (31.3%, P = .015). Subgroup analysis revealed that patients with the highest blood load (Hijdra 30-42) experienced a significant reduction in hydrocephalus (45.8% vs 22.5%, P = .026). By contrast, no significant effects were observed in patients with lower Hijdra scores. Multivariate analysis confirmed that the Hijdra score was a significant predictor of CSH in the standard care group (P = .008) but not in the ABCD-treated group (P = .843).</p><p><strong>Conclusion: </strong>aSAH patients selected for ABCD therapy had a significantly lower incidence of shunt-dependent hydrocephalus compared with matching controls. ABCD therapy may be an important preventive strategy in patients with severe subarachnoid hemorrhage.</p>\",\"PeriodicalId\":19276,\"journal\":{\"name\":\"Neurosurgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1227/neu.0000000000003756\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1227/neu.0000000000003756","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景与目的:慢性分流依赖性脑积水(CSH)是动脉瘤性蛛网膜下腔出血(aSAH)后常见且严重的并发症。主动血液清除率和延迟性脑缺血预防(ABCD)治疗,采用鞘内尿激酶和尼莫地平冲洗,目的是增强血液清除率,预防血管痉挛。本研究评估ABCD治疗是否能降低aSAH患者CSH的发生率。方法:采用配对分析方法,将160例接受ABCD治疗的aSAH患者与160例对照组进行比较。患者在最佳拟合模型的基础上配对,包括世界神经外科医生联合会的分级、年龄、脑疝、脑出血和初始Hijdra评分。通过Hijdra评分对患者进行分层,以考虑血负荷。采用χ2检验比较各组间CSH的发生率,采用多变量病因特异性Cox比例风险模型评估发生分流依赖性脑积水的时间。此外,还进行了多变量logistic回归,以确定脑积水的预测因素。结果:ABCD组CSH发生率(19.4%)明显低于标准治疗组(31.3%,P = 0.015)。亚组分析显示,血负荷最高的患者(Hijdra 30-42)脑积水发生率显著降低(45.8% vs 22.5%, P = 0.026)。相比之下,在Hijdra评分较低的患者中没有观察到明显的效果。多因素分析证实,Hijdra评分是标准治疗组CSH的重要预测因子(P = 0.008),但在abcd治疗组则不然(P = 0.843)。结论:选择ABCD治疗的aSAH患者与匹配对照组相比,分流依赖性脑积水的发生率显著降低。ABCD治疗可能是严重蛛网膜下腔出血患者的重要预防策略。
Active Blood Clearance and Delayed Cerebral Ischemia Prevention Therapy Reduces Shunt-Dependent Hydrocephalus in Patients With Aneurysmal Subarachnoid Hemorrhage.
Background and objectives: Chronic shunt-dependent hydrocephalus (CSH) is a common and serious complication after aneurysmal subarachnoid hemorrhage (aSAH). Active blood clearance and delayed cerebral ischemia prevention (ABCD) therapy, using intrathecal urokinase and nimodipine irrigation, aims to enhance blood clearance and prevent vasospasm. This study evaluates whether ABCD therapy reduces the incidence of CSH in aSAH patients.
Methods: A matched-pairs analysis was performed and 160 aSAH patients who had received ABCD therapy were compared with 160 controls. Patients were paired on the basis of a best fit model including the World Federation of Neurological Surgeons grade, age, cerebral herniation, intracerebral hemorrhage, and the initial Hijdra score. Patients were stratified by Hijdra score to account for blood load. The incidence of CSH was compared between groups using χ2 tests, whereas a multivariable cause-specific Cox proportional hazards model was used to assess time to shunt-dependent hydrocephalus. In addition, multivariate logistic regression was performed to identify predictors of hydrocephalus.
Results: The incidence of CSH was significantly lower in the ABCD group (19.4%) compared with the standard care group (31.3%, P = .015). Subgroup analysis revealed that patients with the highest blood load (Hijdra 30-42) experienced a significant reduction in hydrocephalus (45.8% vs 22.5%, P = .026). By contrast, no significant effects were observed in patients with lower Hijdra scores. Multivariate analysis confirmed that the Hijdra score was a significant predictor of CSH in the standard care group (P = .008) but not in the ABCD-treated group (P = .843).
Conclusion: aSAH patients selected for ABCD therapy had a significantly lower incidence of shunt-dependent hydrocephalus compared with matching controls. ABCD therapy may be an important preventive strategy in patients with severe subarachnoid hemorrhage.
期刊介绍:
Neurosurgery, the official journal of the Congress of Neurological Surgeons, publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. For professionals aware of the rapid pace of developments in the field, this journal is nothing short of indispensable as the most complete window on the contemporary field of neurosurgery.
Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.